Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in JuneGlobeNewsWire • 05/27/25
TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?Zacks Investment Research • 05/27/25
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and AsthmaGlobeNewsWire • 05/27/25
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 NotesGlobeNewsWire • 05/22/25
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing DebtGlobeNewsWire • 05/20/25
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth StrategyGlobeNewsWire • 05/20/25
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031GlobeNewsWire • 05/19/25
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior NotesGlobeNewsWire • 05/19/25
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth StrategyGlobeNewsWire • 05/15/25
TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock UpZacks Investment Research • 05/08/25
Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot MomentumBenzinga • 05/07/25
Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call TranscriptSeeking Alpha • 05/07/25
Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter ReportInvestors Business Daily • 05/07/25
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook ImprovedGlobeNewsWire • 05/07/25
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?Benzinga • 05/05/25
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q1 EarningsZacks Investment Research • 05/05/25